Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 6/20 | 0.36 |
| ▸ | JAK2 | O60674 | 2/20 | 0.36 |
| ▸ | JAK1 | P23458 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4590166 | 0.76 | NPC1 (0.55) | MEN1KMT2ACYP1A2NPSR1MAPT | |
| SCHEMBL1506466 | 0.76 | NPC1 (0.55) | MEN1KMT2ACYP1A2NPSR1MAPT | |
| SCHEMBL1506463 | 0.76 | NPC1 (0.55) | MEN1KMT2ACYP1A2NPSR1MAPT | |
| SCHEMBL4822117 | 0.74 | CA12 (0.50) | MEN1KMT2ACYP1A2NPSR1MAPT | |
| SCHEMBL8649563 | 0.68 | SMN1; SMN2 (0.60) | MAPTTP53 | |
| SCHEMBL9045231 | 0.68 | SMN1; SMN2 (0.60) | MAPTTP53 | |
| SCHEMBL14341919 | 0.67 | EPHX1 (0.59) | MEN1KMT2ACYP1A2NPSR1MAPT | |
| SCHEMBL733725 | 0.67 | EPHX1 (0.59) | MEN1KMT2ACYP1A2NPSR1MAPT | |
| SCHEMBL10578571 | 0.67 | MEN1 (0.67) | MEN1KMT2ACYP1A2NPSR1MAPT | |
| SCHEMBL4492505 | 0.67 | KMT2A (0.57) | MEN1KMT2ACYP1A2NPSR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741333-B2 | Quinazoline derivatives, their preparation, their use, and medicaments comprising them | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-22 | — | — | US | disclosed |
| US-7741333-B2 | Quinazoline derivatives, their preparation, their use, and medicaments comprising them | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-22 | — | — | US | disclosed |
| US-7741333-B2 | Quinazoline derivatives, their preparation, their use, and medicaments comprising them | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-22 | — | — | US | disclosed |
| EP-2041143-A1 | QUINAZOLINE DERIVATIVES, THEIR PREPARATION, THEIR USE AS TYROSINE KINASE INHIBITORS AND MEDICAMENTS COMPRISING THEM | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-04-01 | — | — | EP | disclosed |
| US-20080019922-A1 | QUINAZOLINE DERIVATIVES, THEIR PREPARATION, THEIR USE, AND MEDICAMENTS COMPRISING THEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-01-24 | — | — | US | disclosed |
| US-20080019922-A1 | QUINAZOLINE DERIVATIVES, THEIR PREPARATION, THEIR USE, AND MEDICAMENTS COMPRISING THEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-01-24 | — | — | US | disclosed |
| US-20080019922-A1 | QUINAZOLINE DERIVATIVES, THEIR PREPARATION, THEIR USE, AND MEDICAMENTS COMPRISING THEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-01-24 | — | — | US | disclosed |
| WO-2007147577-A1 | QUINAZOLINE DERIVATIVES, THEIR PREPARATION, THEIR USE AS TYROSINE KINASE INHIBITORS AND MEDICAMENTS COMPRISING THEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080019922-A1 | QUINAZOLINE DERIVATIVES, THEIR PREPARATION, THEIR USE, AND MEDICAMENTS COMPRISING THEM | XDH, CYP1A2, RECQL | MEN1 572/4885KMT2A 1951/4885CYP1A2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.